


Stabilis



Cefotaxime sodium



Noms commerciaux

Alvim	Mexique
Antadar	Portugal
Aximad	Italie
Batixim	Italie
Betaksim	Turquie
Biotaksym	Pologne
Cefotax	Brésil, Roumanie
Cefotaxim	Allemagne
Ceftax	Arabie Saoudite
Centiax	Italie
Claforan	Allemagne, Arabie Saoudite, Autriche, Belgique, Brésil, Canada, Danemark, Egypte, Espagne, Finlande, France, Grèce, Hongrie, Italie, Maroc, Pays bas, Russie, Suède, Suisse, Thaïlande, Turquie, Vénézuéla
Clafotax	Arabie Saoudite
Letynol	Grèce
Lirgosin	Italie
Molelant	Grèce
Naspor	Grèce
Phacocef	Grèce
Primocef	Arabie Saoudite
Ralopar	Portugal
Rantaksyn	Pologne
Refotax	Italie
Salocéf	Italie
Sefotak	Turquie
Spectrocef	Italie
Spirosine	Grèce
Stoparen	Grèce
Tarcefoksym	Pologne
Taxocéf	Turquie
Tirotax	Pologne
Totam	Afrique du sud, Arabie Saoudite
Zariviz	Italie



Stabilité des solutions

		20 mg/ml	24°C		24			421
		20 mg/ml	2-8°C		24			1452
		20 mg/ml	25°C		24			1452
		10 mg/ml	-10°C		112			593
		10 mg/ml	24°C		24			593
		10 mg/ml	4°C		22			593
		20 mg/ml	24°C		24			421
		10 mg/ml	-20°C		90			592
		10 mg/ml	25°C		24			592
		10 mg/ml	4°C		4			592
		0,86 mg/ml	37°C		6			2374
		0,92 mg/ml	25°C		24			2374
		0,80 mg/ml	37°C		6			2374
		0,87 mg/ml	25°C		24			2374
		20 mg/ml	2-8°C		24			1452
		20 mg/ml	25°C		24			1452
		125 mg/ml	20-25°C		6			4268
		83,3 mg/ml	20-25°C		6			4268
		50 mg/ml	25°C		24			1711
		50 mg/ml	5°C		18			1711
		5 & 40 mg/ml	25°C		24			604



Stabilité en mélange

		20 mg/ml	24°C		Clindamycin phosphate : 9 mg/ml	24		421
		20 mg/ml	24°C		Clindamycin phosphate : 9 mg/ml	24		421
		10 mg/ml	28°C		Metronidazole : 5 mg/ml	12		281
		10 mg/ml	5°C		Metronidazole : 5 mg/ml	96		281
		5 mg/ml	20°C		Tinidazole : 2 mg/ml	8		2185



Facteur influençant la stabilité

4,5 < pH < 5,5



592



Compatibilités

	Cefotaxime sodium : 20 mg/ml Aciclovir sodium : 5 mg/ml		336	
		Cefotaxime sodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
	Cefotaxime sodium : 100 mg/ml Alprostadil : 15 µg/ml		3201	
	Cefotaxime sodium : 20 mg/ml Amifostine : 10 mg/ml		3	
		Cefotaxime sodium Amikacin sulfate		3549
	Cefotaxime sodium : 40 mg/ml Amiodarone hydrochloride : 9 mg/ml		4698	
	Cefotaxime sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824	
		Cefotaxime sodium Amphotericin B		3871
		Cefotaxime sodium : 200 mg/ml Azithromycine : 2 mg/ml		1800
	Cefotaxime sodium : 20 mg/ml Aztreonam : 40 mg/ml		99	
	Cefotaxime sodium : 20 mg/ml Bivalirudin : 5 mg/ml		1713	
	Cefotaxime sodium : 100 mg/ml Caffeine : 10 mg/ml		3964	
	Cefotaxime sodium : 20 mg/ml Cisatracurium besylate : 0.1 mg/ml		299	
		Cefotaxime sodium : 20 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Cefotaxime sodium : 20 mg/ml Cisatracurium besylate : 2 mg/ml		299
	Cefotaxime sodium : 20 mg/ml Clindamycin phosphate : 9 mg/ml			421
	Cefotaxime sodium Clindamycin phosphate			3526
	Cefotaxime sodium : 95 mg/ml Cloxacillin sodium : 100 mg/ml		3012	
	Cefotaxime sodium : 20 mg/ml Dexmedetomidine : 4 µg/ml		1712	
	Cefotaxime sodium : 10 & 180 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198	
	Cefotaxime sodium Dimenhydrinate		2087	

		Cefotaxime sodium : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Cefotaxime sodium Erythromycin lactobionate		3674
		Cefotaxime sodium : 20 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cefotaxime sodium : 20 mg/ml Famotidine : 2 mg/ml		215
		Cefotaxime sodium : 20 mg/ml Famotidine		397
		Cefotaxime sodium : 20 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Cefotaxime sodium : 20 mg/ml Fentanyl citrate : 50 µg/ml		63
		Cefotaxime sodium : 20 mg/ml Filgrastim : 30 µg/ml		244
		Cefotaxime sodium : 20 mg/ml Fluconazole : 2 mg/ml		496
		Cefotaxime sodium : 20 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Cefotaxime sodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cefotaxime sodium Gentamicin sulfate		3520
		Cefotaxime sodium Gentamicin sulfate		3643
		Cefotaxime sodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Cefotaxime sodium : 41.6 & 125 mg/ml Heparin sodium : 208 UI/ml	 	4254
		Cefotaxime sodium : 10 mg/ml Heparin sodium : 5000 UI/ml		3125
		Cefotaxime sodium : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Cefotaxime sodium : 20 mg/ml Hetastarch : 60 mg/ml		472
		Cefotaxime sodium : 83.3 mg/ml Hydrocortisone sodium succinate : 2 mg/ml	 	4254
		Cefotaxime sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Cefotaxime sodium : 83.3 mg/ml Insulin : 1 UI/ml	 	4254
		Cefotaxime sodium : 100 mg/ml	RL	4603
		Cefotaxime sodium : 20 mg/ml		1415
		Cefotaxime sodium : 60 mg/ml		316
		Cefotaxime sodium : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Cefotaxime sodium : 200 mg/ml Levofloxacin : 5 mg/ml		1072
		Cefotaxime sodium : 300 mg/ml		999

	Cefotaxime sodium : 200 mg/ml		939
	Cefotaxime sodium : 20 mg/ml		301
	Cefotaxime sodium : 83.3 mg/ml Levetiracetam : 20.83 mg/ml		4254
	Cefotaxime sodium : 10 mg/ml Lorazepam : 0.33 mg/ml		186
	Cefotaxime sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
	Cefotaxime sodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
	Cefotaxime sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
	Cefotaxime sodium : 20 mg/ml Metronidazole : 5 mg/ml		1035
	Cefotaxime sodium Metronidazole		3594
	Cefotaxime sodium : 10 mg/ml Metronidazole : 5 mg/ml		281
	Cefotaxime sodium : 10 mg/ml Midazolam hydrochloride : 5 mg/ml		186
	Cefotaxime sodium : 20 mg/ml Midazolam hydrochloride : 1 mg/ml		176
	Cefotaxime sodium : 20 mg/ml Morphine sulfate : 1 mg/ml		405
	Cefotaxime sodium N-acetylcysteine : 200 mg/ml		3766
	Cefotaxime sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Cefotaxime sodium : 40 mg/ml Nefopam : 0,16 mg/ml		4698
	Cefotaxime sodium Omeprazole sodium		3871
	Cefotaxime sodium Omeprazole sodium		3871
	Cefotaxime sodium : 20 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Cefotaxime sodium : 83.3 mg/ml Ornidazole : 31.25 mg/ml		4254
	Cefotaxime sodium Pantoprazole sodium		2090
	Cefotaxime sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
	Cefotaxime sodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Cefotaxime sodium : 20 mg/ml Pentamidine isetionate : 3 mg/ml		275
	Cefotaxime sodium : 100 mg/ml Pentoxifyllin : 5 mg/ml		4538
	Cefotaxime sodium : 300 mg/ml Pentoxifyllin : 5 mg/ml		4538
	Cefotaxime sodium : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		405

		Cefotaxime sodium : 25 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Cefotaxime sodium : 20 mg/ml Propofol : 10 mg/ml	∅	300
		Cefotaxime sodium : 20 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
		Cefotaxime sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Cefotaxime sodium : 20 mg/ml Sargramostim : 10 µg/ml	▲	335
		Cefotaxime sodium : 20 mg/ml Teniposide : 0.1 mg/ml	◆	905
		Cefotaxime sodium : 83.3 mg/ml Thiamine hydrochloride : 0.4 mg/ml	◆	4254
		Cefotaxime sodium : 100 mg/ml Thiopental sodium : 25 mg/ml	▲	3767
		Cefotaxime sodium : 20 mg/ml Thiotepa : 1 mg/ml	◆	249
		Cefotaxime sodium : 5 mg/ml Tinidazole : 2 mg/ml		2185
		Cefotaxime sodium : 1 & 10 mg/ml Vancomycin hydrochloride : 20 mg/ml	◆	1674
		Cefotaxime sodium : 1 >> 200 mg/ml Vancomycin hydrochloride : 2 mg/ml	◆	1674
		Cefotaxime sodium : 100 mg/ml Vancomycin hydrochloride : 5 & 12,5 mg/ml	💧	260
		Cefotaxime sodium : 50 & 200 mg/ml Vancomycin hydrochloride : 20 mg/ml	◆	1674
		Cefotaxime sodium : 100 mg/ml Vancomycin hydrochloride : 25 & 30 mg/ml		260
		Cefotaxime sodium : 4 mg/ml Verapamil hydrochloride : 0.08 mg/ml	▲◆	1057
		Cefotaxime sodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
260	Revue	Szof C, Walker PC. Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration. Am J Hosp Pharm 1993 ; 50: 2054, 2057.
275	Revue	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
281	Revue	Belliveau PP, Nightingale CH, Quintiliani R. Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 1561-1563.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.

301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
421	Revue	Foley PT, Bosso JA, Bair JN, Townsend RJ. Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm 1985 ; 42: 839-843.
472	Revue	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
592	Revue	Barthes D, Fauconneau B, Martin JP, Courtois P. Effects of storage temperature and pH on the stability of cefotaxime in PVC bags. J Pharm Clin 1989 ; 8: 101-106.
593	Revue	Das Gupta V. Stability of cefotaxime sodium as determined by High-Performance Liquid Chromatography. J Pharm Sci 1984 ; 73: 565-567.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.







999	Revue	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Revue	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	Revue	Muller HJ, Howe K, Frank C, Haker I. Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1674	Revue	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1711	Revue	Das Gupta V. Stability of cefotaxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2002 ; 6: 234-236.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.

1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2185	Revue	Guo P, Li X, Wan J, You A. Study on the compatibility of cefotaxime with tinidazole in glucose injection. J Pharm Biomed Anal 2007 ; 43: 1849-1853.
2374	Revue	CM Paap CM, Nahata MC. Stability of cefotaxime in two peritoneal dialysis solutions Am J Hosp Pharm 1990 ; 47: 147 - 150.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3125	Revue	Baker D S, Waldrop Bruce, Arnold John. Compatibility and Stability of Cefotaxime, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin. Int J Pharm Compound 2010 ; 14, 4: 346-349.
3201	Revue	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.

3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3871	Poster	Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M. Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ? Synpreph Congress Clermont Ferrand, France 2016
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4268	Revue	D'Huart E, Vigneron J, Blaise F, Charmillon A, Demoré B. Physicochemical Stability of Cefotaxime Sodium in Polypropylene Syringes at High Concentrations for Intensive Care Units. Pharmaceutical Technology in Hospital Pharmacy 2019
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4698	Revue	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 Lumière
 Heure	 Chlorure de sodium 0,9%
 A l'abri de la lumière	 Non précisée
 Polyvinyl chlorure	 Jour
 Glucose 5%	 Dianéal® PD1 1.5% glucose (Baxter)
 Dianéal® PD1 4.25% glucose (Baxter)	 Polyolefine
 Seringue polypropylène	 Elastomère en polyisoprène
 Stabilité en mélange	 Solvant
 Molécule	 Non précisé
 Facteur influençant la stabilité	 Provoque
 Augmentation stabilité	 Compatibilités
 Compatible	 Précipitation immédiate
 Incompatible	 Instabilité chimique
 Précipitation en 1 heure	 Aucun
 Turbidité immédiate	 Turbidité en 4 heures
 Eau pour préparation injectable	 Incompatibilité non précisée
 Précipitation en 4 heures	 Turbidité en 1 heure
 Solvant spécifique	RL Ringer lactate
 Nutrition parentérale (mélange ternaire)	 Nutrition parentérale (mélange binaire)
 Changement de couleur à 4 heures	 Voie d'administration
 Intraveineuse	 Perfusion intraveineuse
 Intramusculaire	 Bibliographie
 Dictionnaire	